NCT04484857 - Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants | Biotech Hunter

Enrollment

283

Participants

Timeline

Start Date

July 22, 2020

Primary Completion Date

July 9, 2021

Study Completion Date

September 17, 2021

Conditions

Anemia Associated With End Stage Renal Disease

Interventions

DRUG

Roxadustat

Roxadustat will be administered per dose and schedule specified in the arm description.

Trial Locations (26)

10461

Investigational Site, The Bronx

23502

Investigational Site, Norfolk

30458

Investigational Site, Statesboro

30720

Investigator Site, Dalton

33024

Investigational Site, Hollywood

33134

Investigational Site, Coral Gables

48066

Investigational Site, Roseville

64111

Investigational Site, Kansas City

71603

Investigator Site, Pine Bluff

75237

Investigator Site, Dallas

77004

Investigational Site, Houston

78202

Investigator Site, San Antonio

78211

Investigator Site, San Antonio

78221

Investigator Site, San Antonio

78229

Investigational Site, Austin

Investigational Site, San Antonio

78251

Investigational Site, San Antonio

78521

Investigator Sites, San Antonio

79924

Investigational Site, El Paso

80230

Investigational Site, Denver

87301

Investigator Site, Gallup

89178

Investigational Site, Las Vegas

90703

Investigational Site, Cerritos

92394

Investigational Site, Victorville

99515

Alaska, Anchorage

06112

Investigational Site, Hartford